Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04469205
Other study ID # IC 2017-06
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date October 5, 2020
Est. completion date March 8, 2024

Study information

Verified date January 2024
Source Institut Curie
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluate the impact of coaching sessions on the return to work rate (number of patients returning at work / total number of patients per arm) 6 months after inclusion in the study for breast cancer in professionnally active patients.


Recruitment information / eligibility

Status Terminated
Enrollment 69
Est. completion date March 8, 2024
Est. primary completion date June 15, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: Any patient active at the time of the diagnosis of breast cancer, treated consecutively at the Institut Curie during the study period, and whose first treatment will be surgery, will be offered participation in the study. 1. Invasive non-metastatic breast cancer, treated first by surgery 2. Age = 18 and = 60 years 3. Active woman at the time of diagnosis 4. Patient with internet access and email address 5. Patient affiliated with a social security scheme, speaking and reading French 6. Signature of informed consent Exclusion Criteria: 1. In situ breast cancer 2. History of breast cancer 3. Metastatic breast cancer 4. Inflammatory Breast Cancer 5. Woman with a life expectancy <6 months at the time of diagnosis (in relation to other serious chronic diseases) 6. Persons deprived of liberty or under guardianship 7. Impossibility to submit to the medical follow-up of the test for geographical, social or psychological reasons

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Coaching sessions
There are 3 sessions : the first session will last 1h30 and will be in consultation within the Institut Curie. The second session will last 1h30 and will be done remotely (by phone or by videoconference). The duration of the 3rd and last session will be adapted according to the needs of each patient and will last a maximum of 1 hour. It will also be done remotely (by phone or by videoconference).

Locations

Country Name City State
France Institut Curie Paris
France Institut Curie Saint-Cloud

Sponsors (1)

Lead Sponsor Collaborator
Institut Curie

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Impact of coaching sessions on the return to work rate (number of patients returning at work / total number of patients per arm) 6 months after inclusion in the study The rate of patients returning to work (part-time or full-time) for more than 2 weeks to 6 months of inclusion in the study in each group. 6 months
Secondary Quality of the return to work Evaluation of the quality of the return to work at 6 and 12 months after inclusion by questionnaire VOW / QFT (in case of return to work only).
Evaluation scale : 1=never to 4=ever
6 and 12 months
Secondary Sustainability of the return to work Evaluation of the durability of the return to work at 6 and 12 months after inclusion by registration by the patients of the number of days off work and / or working time arrangement 6 and 12 months
Secondary Impact of the return to work / work stoppage on the quality of life Evaluation of the impact of return to work / work stoppage on the quality of life estimated by QLQ-C30 questionnaire at baseline and at 6 and 12 months post-inclusion 6 and 12 months
Secondary The production losses related to presenteeism during maintenance or return to work Evaluation of production losses related to presenteeism at the time of maintenance or return to work at 6 and 12 months post inclusion, by collecting the number of days worked during the study period (12 months) 6 and 12 months
Secondary The production losses related to presenteeism during maintenance or return to work Evaluation of the loss of productivity during a professional activity : in case of return to work, the "Work limitation questionnaire" will be completed at 6 and 12 months after inclusion 6 and 12 months
Secondary The determinants of return to work (factors associated with a return to work "successful": early, sustainable and quality) Determining the determinants of return to work at 6 and 12 months post inclusion using the QLQ-BR23questionnaire.
Evaluation scale : 0=not at all to 4=a lot
12 months
Secondary The determinants of return to work (factors associated with a return to work "successful": early, sustainable and quality) Determining the determinants of return to work at 6 and 12 months post inclusion using the QLQ-FA12 questionnaire.
Evaluation scale : 0=not at all to 4=a lot
6 and 12 months
Secondary The determinants of return to work (factors associated with a return to work "successful": early, sustainable and quality) Determining the determinants of return to work at 6 and 12 months post inclusion using the HADS questionnaire.
Anxiety scale : 3=most of the time to 0=never Depression scale : 3=never to 0= most of the time
6 and 12 months
Secondary The determinants of return to work (factors associated with a return to work "successful": early, sustainable and quality) Determining the determinants of return to work at 6 and 12 months post inclusion using the SSQ6 questionnaire.
Evaluation scale : 1=really dissatisfied to 6 =really satisfied
6 and 12 months
Secondary The determinants of return to work (factors associated with a return to work "successful": early, sustainable and quality) Determining the determinants of return to work at 6 and 12 months post inclusion using the Brief Cope questionnaire.
Evaluation scale : 0=not at all to 4=absolutely
6 and 12 months
Secondary The determinants of return to work (factors associated with a return to work "successful": early, sustainable and quality) These determinants will also be evaluated through the collection of socio-demographic data, cancer characteristics and treatments administered. 6 and 12 months
Secondary The medico-economic impact of returning to work Evaluation of the medico-economic impact of return to work by comparing the costs of care in the two groups 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A